Merck/DeCode: Just Another Pharmacogenomics Deal?
Merck's deal with deCode provides valuable endorsement of the Icelandic firm's clinical development expertise, and reinforces the Big Pharma's partnering drive. But although interesting scientifically-the partners claim the deal is different in scope and nature to most pharmacogenomics projects-this alliance is unlikely, in the near term at least, to improve Merck's chances of late-stage success.
You may also be interested in...
Despite a strong trend among Big Pharma towards in-licensing over the last decade, Merck & Co. hasn't been particularly willing to embrace research ideas outside its own labs. But that's changing. Merck's new European in-licensing initiative proves that the Big Pharma recognizes, and hopes to access, the wealth of science and potential deals beyond US borders.
deCODE's recent in-licensing deal with Bayer suggests the biotech's population genetics approach could be set to bear fruit. By in-licensing a compound already shown to be safe, deCODE gets to leapfrog time-consuming drug discovery and early development and move straight into Phase II with its first clinical candidate, saving valuable time and money, and validating its discovery approach to pave the way for additional similar deals. But this inexpensive deal was made for an apparently unwanted compound, and predicated on so-far unsubstantiated claims by deCODE about the link between an unnamed target and heart attack.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.